FRM
AMRX icon

Fox Run Management’s Amneal Pharmaceuticals AMRX Stock Holding History

Fox Run Management’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-33,724
Closed -$425K – 886
2025
Q4 		$425K Buy
+33,724
New +$386K 0.07% 565
2025
Q1 		– Sell
-20,435
Closed -$162K – 896
2024
Q4 		$162K Buy
20,435
+8,342
+69% +$70K 0.03% 776
2024
Q3 		$101K Buy
+12,093
New +$94.6K 0.02% 741
2021
Q3 		– Sell
-14,184
Closed -$73K – 455
2021
Q2 		$73K Buy
+14,184
New +$80.6K 0.07% 325
2019
Q3 		– Sell
-24,749
Closed -$177K – 352
2019
Q2 		$177K Buy
+24,749
New +$253K 0.12% 377
2018
Q3 		– Sell
-13,872
Closed -$228K – 560
2018
Q2 		$228K Buy
+13,872
New +$243K 0.07% 533

Other funds holding AMRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Fox Run Management's AMRX Position: Q1 2026 in Review

Fox Run Management sold out of Amneal Pharmaceuticals (AMRX) in Q1 2026, closing a stake of 33,724 shares — an estimated $425K sold.

Fox Run Management first reported a position in AMRX in Q2 2018 and held it in 6 quarters. The position peaked at $425K in Q4 2025. 315 funds tracked by Wall St. Rank hold AMRX as of Q1 2026.

  • Fox Run Management reported no remaining Amneal Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Fox Run Management sold 33,724 Amneal Pharmaceuticals shares in Q1 2026, an estimated $425K.
  • Fox Run Management first reported a position in Amneal Pharmaceuticals in Q2 2018 and held it in 6 quarters.
  • Fox Run Management's Amneal Pharmaceuticals position peaked at $425K in Q4 2025.
  • 315 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q1 2026.

Based on Fox Run Management's 13F filing for Q1 2026, filed 12 May 2026.